FocusOn Neurology
  • Biozone
  • Multiple Sclerosis
  • Migraine Research Library
  • LGS & Dravet Syndrome
  • Tardive Dyskinesia
  • Myasthenia Gravis
  • Neurofibromatosis
  • hATTR-PN
  • MDA 2024
  • CIDP Awareness Month
  • Alzheimer's Awareness Month
  • Anticoagulation Reversal Knowledge & Learning Center
  • PNS 2024 Annual Meeting Highlights
  • Parkinson's Disease
  • AES Annual Meeting 2025
  • Epilepsy Knowledge Hub
  • Stroke Awareness Month
  • Multiple Sclerosis
  • Migraine Research Library
  • LGS & Dravet Syndrome
  • Tardive Dyskinesia
  • Myasthenia Gravis
  • Neurofibromatosis
  • hATTR-PN
  • MDA 2024
  • CIDP Awareness Month
  • Alzheimer's Awareness Month
  • Anticoagulation Reversal Knowledge & Learning Center
  • PNS 2024 Annual Meeting Highlights
  • Parkinson's Disease
    • Peer-reviewed articles
    • Supplemental educational content
    • Test Your Knowledge
  • AES Annual Meeting 2025
  • Epilepsy Knowledge Hub

Advanced Search

Advanced Search

  • Featured:
  • Biozone
  • Stroke Awareness Month
 

KCNQ2 Variants in Neonatal Epilepsy: Clinical Characteristics and Neurodevelopmental Outcomes in 30 Patients

June 2026 | Neurology: Genetics

Share:
Epilepsy Awareness Month Peer-Reviewed Articles Page

Read Full Article

Abstract

Background and Objectives

The aim of this study was to characterize clinical features, genetic architecture, treatment responses, and neurodevelopmental outcomes in neonatal epilepsy associated with KCNQ2 variants and to delineate genotype-phenotype correlations.

Methods

We conducted a retrospective, two-center study of 30 neonates from 2019 to 2024. All patients underwent whole-exome sequencing with Sanger confirmation and, at last follow-up, were classified, according to International League Against Epilepsy criteria as having self-limited (familial) neonatal epilepsy (SeL[F]NE) or developmental and epileptic encephalopathy (DEE). Primary outcomes were seizure freedom by 6 months and milestone-based three-level neurodevelopment (normal/mild/severe). Clinical/EEG/MRI features and variant class/topology were compared across phenotypes.

Results

Most infants presented in the first week of life (median 3 days), typically with focal tonic seizures. EEG abnormalities were common (90%); burst-suppression/profound discontinuity consistently signaled adverse neurodevelopment. MRI was often normal (53%) or nonspecific. We identified 29 distinct variants (32 occurrences) across 30 patients. Twenty-eight carried a single heterozygous variant, and 2 carried 2 heterozygous variants (phase not determined); missense variants predominated (21/30, 70%). Clear topology-phenotype patterns emerged: transmembrane missense variants—especially S5-pore-S6—were enriched in DEE, whereas C-terminal/nontransmembrane variants were associated with SeL(F)NE and benign outcomes. At the last follow-up, SeL(F)NE accounted for 63% and DEE 37%. Seizure freedom reached 93%. Oxcarbazepine was often associated with seizure control after phenobarbital nonresponse, but this observational signal should not be interpreted as causal. Neurodevelopment was normal in 63%; delays occurred only within the DEE cohort. All 5 single-allele truncating/NMD lesions (CNV deletion, canonical splice-site, 2 nonsense, 1 frameshift) aligned with SeL(F)NE, whereas the 2 individuals with 2 heterozygous variants were classified as DEE with marked impairment; however, phase was not determined and 1 recurrent variant (p.E515D) was classified as likely benign, precluding inference of 2 pathogenic alleles.

Share

Modal body text goes here.

FocusOn logo
  • Articles
  • Multimedia
  • Blog
  • Resources
  • About FocusOn
  • Privacy Policy
  • Terms of Use

© 2026 Wolters Kluwer. All right reserved.

Your Privacy

To give you the best possible experience we use cookies and similar technologies. We use data collected through these technologies for various purposes, including to enhance website functionality, remember your preferences, show the most relevant content, and show the most useful ads. You can select your preferences by clicking the link. For more information, please review our Privacy and Cookie Policy.

|
|

Cookie Policy

Information about our use of cookies

Wolters Kluwer ("we" or "us") wants to inform you about the ways we process your personal information. In this Privacy & Cookie Notice we explain what personal information we collect, use and disclose.

Personal information means any data relating to an individual who can be identified, directly or indirectly, based on that information. This may include information such as names, contact details, (online) identification data, online identifiers, or other characteristics specific to that individual.

Read More